国泰海通证券股份有限公司关于 普源精电科技股份有限公司差异化分红事项的核查意见 国泰海通证券股份有限公司（以下简称"保荐机构"）作为普源精电科技股 份有限公司（以下简称"公司"、"普源精电"或"发行人"）首次公开发行股 票并在科创板上市、2023年以简易程序向特定对象发行股票的保荐机构及持续督 导机构，根据《中华人民共和国公司法》《中华人民共和国证券法》《证券发行 上市保荐业务管理办法》《上市公司股份回购规则》《上海证券交易所上市公司 自律监管指引第7号——回购股份》《上海证券交易所上市公司自律监管指南第 2号——业务办理》等法律法规，对公司2024年度利润分配所涉及的差异化分红 相关事项进行了审慎核查，核查情况及核查意见如下： 一、差异化分红原因 2024年2月4日，公司召开第二届董事会第十四次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》，公司董事会同意公司使用自有资 金通过上海证券交易所系统以集中竞价交易方式回购公司已发行的部分人民币 普通股（A股），在未来适宜时机用于股权激励计划。回购股份的资金总额不低 于人民币3,000.00万元（含），不超过人民币5,000.00万元（含）。回 ...

证券代码：688337 证券简称：普源精电 公告编号：2025-032 普源精电科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/17 | 2025/7/18 | 2025/7/18 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025年 6月 25 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 2024年年度权益分派实施公告 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 差异化分红送转方案： （1） 本次差异化分红方案 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.40元 相关日期 根据公司 2024 年年度股东大会审议通过的《关于公司 2024 年度利润分配方 案的议案》，公司 20 ...

Industry Rating - The report maintains an "Outperform" rating for the scientific instruments industry, consistent with the previous rating [1]. Core Insights - The scientific instruments market in China surpassed 220 billion yuan in 2023, with a growth rate exceeding 12%. The market is dominated by high-end foreign brands, and there is a significant push for domestic alternatives driven by government policies [2][12]. - The domestic market for mass spectrometers reached 16.712 billion yuan in 2023, with foreign companies holding over 90% of the global market share. The import rate for mass spectrometers has decreased from 89% in 2018 to 81% in 2023, indicating a gradual shift towards domestic production [3][41]. - The electronic measurement instruments market is projected to exceed 40 billion yuan in 2024, with a notable focus on mid-to-high-end products. The market for oscilloscopes is expected to reach 650 million USD by 2025 [4]. Summary by Sections 1. Scientific Instruments Industry - The scientific instruments industry is characterized by high-end foreign brands dominating the market, while domestic brands struggle to gain market share. The government has introduced various policies to promote domestic innovation and application of scientific instruments [2][24]. 2. Scientific Analysis Instruments - The market for scientific analysis instruments is vast, with mass spectrometers and chromatographs showing low domestic production rates. The mass spectrometer market is expected to grow significantly, with a focus on high-resolution and triple quadrupole models as key areas for domestic manufacturers to target [25][50]. 3. Electronic Measurement Instruments - The electronic measurement instruments market is rapidly expanding, with a projected market size of 16.307 billion USD globally by 2024. The domestic market is expected to exceed 40 billion yuan, with a significant portion of high-end products still being imported [4][6]. 4. Policy Guidance - Recent government policies have aimed to support the development of domestic scientific instruments, including tax exemptions for imported instruments used in research and education, which will lower costs for research institutions [21][24].

证券代码：688337 证券简称：普源精电 公告编号：2025-031 普源精电科技股份有限公司 7 号——回购股份》的相关规定，公司在回购期间，应当在每个月的前 3 个交易 日内公告截至上月末的回购进展情况。现将回购股份的进展情况公告如下： 截至 2025 年 6 月 30 日，公司尚未实施股份回购。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 日~2026 2025 4 | 4 | 月 | 29 | 年 | 月 | 28 | 日 | | 预计回购金额 | 3,000万元~5,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 0万股 | | | | | | | | | 累计已回购股数占总股本比例 | 0% | | | ...

Core Viewpoint - Megatech Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to capitalize on its position as a leading provider of autonomous intelligent systems in the robotics technology application sector in China [3]. Company Overview - Established in 2016, Megatech is recognized as a national-level "specialized and innovative" small giant enterprise and has been listed among the "50 Smartest Companies" by MIT Technology Review [3]. - The company is primarily focused on the sales of autonomous intelligent systems and multi-agent solutions [12]. Financial Performance - Megatech's revenue for the years 2022, 2023, and 2024 is projected to be approximately RMB 455 million, RMB 663 million, and RMB 930 million, respectively [12]. - The company has reported losses of approximately RMB 759 million, RMB 742 million, and RMB 780 million for the same years [12]. Shareholding Structure - The largest shareholder group, consisting of Huang Yuqing, Qiao Zhixin, Zhang Yan, and others, collectively holds about 16.08% of the company's issued share capital [3]. Leadership Team - Huang Yuqing, the founder, chairman, executive director, and CEO, oversees the overall business strategy and management of the company [6]. - Qiao Zhixin serves as the co-founder, executive director, and COO, responsible for internal operations [10]. - Zhang Yan is also a co-founder and executive director, focusing on the management of the smart laboratory business [11].

Core Insights - The article analyzes the salary situation of R&D and sales employees in 50 listed instrument companies in China, highlighting the competitive landscape for talent in the industry [2][3]. R&D Salary Analysis - The average annual salary for R&D personnel in listed instrument companies for 2024 is 232,900 yuan, reflecting a slight increase of 2.64% compared to 2023, indicating a growing emphasis on R&D talent [3]. - There is a significant disparity in R&D salaries among companies, with Mindray Medical leading at 505,100 yuan per year, followed by Puyuan Precision, Meiya Optoelectronics, and others, while some companies offer as low as 100,000 yuan per year [3][5]. - The salary gap may lead to a concentration of R&D talent in top companies, exacerbating the competitive imbalance in the industry [4]. Sales Salary Analysis - The average annual salary for sales personnel in 2024 is 334,000 yuan, showing a growth of 3.66% from the previous year, indicating an increasing reliance on sales teams in a competitive market [9]. - Mindray Medical, Meiya Optoelectronics, and others top the sales salary rankings, with Mindray's sales personnel earning 729,600 yuan per year, reflecting the high value placed on sales talent [9][11]. - The high salary levels in the sales sector are attributed to the technical complexity and high price of instrument products, necessitating skilled sales personnel [10]. Salary Rankings and Implications - The article provides detailed rankings of R&D and sales salaries, showcasing the top 30 companies in each category, which serves as a reflection of the industry's current state [5][11]. - High salaries are often associated with strong performance in technology innovation and market expansion, while lower salaries may lead to talent loss and reduced innovation capacity [14]. - For job seekers, the salary rankings serve as a reference point, emphasizing the importance of considering a company's growth potential and culture alongside salary [14]. Future Outlook - The importance of R&D and sales talent is expected to grow as the instrument industry continues to develop, highlighting the need for companies to attract and nurture talent through competitive compensation and supportive work environments [15].

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company has signed a cooperation agreement with Xi'an University of Electronic Science and Technology to promote its high-end strategy, focusing on deep integration of industry, academia, and research [6] - The company is committed to high-end product development and has seen significant sales growth in its DS80000 series high-end digital oscilloscopes, with strong demand from strategic customers [6] - The electronic measurement instrument industry is expected to continue steady growth, with domestic companies accelerating their technological advancements and narrowing the gap with overseas competitors [6] Financial Data and Profit Forecast - Total revenue is projected to grow from 776 million in 2024 to 1,332 million by 2027, with a compound annual growth rate (CAGR) of approximately 18.2% [5][8] - The net profit attributable to the parent company is expected to increase from 92 million in 2024 to 262 million by 2027, reflecting a significant growth trajectory [5][8] - The company's gross margin is forecasted to improve from 59.1% in 2024 to 62.7% in 2027, indicating enhanced profitability [5]

证券代码：688337 证券简称：普源精电 公告编号：2025-030 普源精电科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 25 日 （二） 股东大会召开的地点：公司会议室（苏州市高新区科灵路 8 号） （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 107 | | --- | --- | | 普通股股东人数 | 107 | | 2、出席会议的股东所持有的表决权数量 | 135,888,826 | | 普通股股东所持有表决权数量 | 135,888,826 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 70.1353 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 70.1353 | （四） 表决方式 ...

上海市石门一路 288 号 兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 junhesh@junhe.com 2024 年年度股东大会的法律意见书 致：普源精电科技股份有限公司 君合律师事务所上海分所（以下简称"本所"）接受普源精电科技股份有限 公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》、中国证券监督管理委员会颁布实施 的《上市公司股东会规则》（以下简称"《股东会规则》"）等中国现行法律、行政 法规和规范性文件（以下简称"中国法律、法规"，为本法律意见书法律适用之 目的，不包括中国香港特别行政区、中国澳门特别行政区及台湾地区法律、法规） 以及《普源精电科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 就公司 2024 年年度股东大会（以下简称"本次股东大会"）有关事宜出具本法 律意见书。 本法律意见书仅就本次股东大会的召集和召开程序、出席本次股东大会人员 的资格、召集人资格、会议表决程序是否符合中国法律、法规及《公司章程》的 规定以及 ...

Group 1 - The company announced a share repurchase plan with a total expected amount between RMB 30 million and RMB 50 million [1] - The repurchase period is set from April 29, 2025, to April 28, 2026 [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] Group 2 - As of May 31, 2025, the company has not yet implemented any share repurchases [2] - The company will adhere to relevant regulations and make repurchase decisions based on market conditions [2] - The company commits to timely information disclosure regarding the progress of the share repurchase [2]